Compare Archer-Daniels-Midland Co (ADM) vs Mesoblast Limited (MESO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Mesoblast Limited — how do they compare? Archer-Daniels-Midland Co trades at $79.86 (market cap $37.69B), while Mesoblast Limited trades at $13.73 (market cap $1.82B). The key difference: Archer-Daniels-Midland Co is far larger — about 20.7× Mesoblast Limited's market cap, and Archer-Daniels-Midland Co pays a 2.66% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ADM | MESO | |
|---|---|---|
Market Cap | $37.69B | $1.82B |
Sector | Consumer Staples | Technology |
52-Week High | $84.11 | $20.96 |
52-Week Low | $53.54 | $10.45 |
Enterprise Value | $47.72B | $1.82B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
MESO trades at $14.33, down 0.35% with a bearish technical signal. The company reported Q1 2025 revenue of $17.20M with a gross margin of 80.52% but significant losses (-$102.14M net income). Recent developments include FDA BLA filing for rexlemestrocel-L in heart failure and a $50M debt facility draw. Analyst consensus shows 45% buy ratings amid high valuation multiples (P/S 30.52).
Outlook hinges on regulatory approvals and commercial execution. The stock offers speculative upside from pipeline catalysts but carries substantial risk from cash burn and clinical trial outcomes. Investors face volatility from binary regulatory events while current fundamentals reflect pre-revenue biotech challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
